Drug treatment of type 2 diabetes mellitus in patients for whom metformin is contraindicated

References

• International Diabetes Federation Global guideline for type 2 diabetes Available from: http://www.idf.org/global-guideline-type-2-diabetes-2012 Accessed September 5, 2013
   Google Scholar
• National Institute for Health and Clinical Excellence Type 2 diabetes: The management of type 2 diabetes (NICE clinical guideline 87) Available from: http://www.nice.org.uk/guidance/CG87 Accessed August 15, 2013
   Google Scholar
• Inzucchi SE Bergenstal RM Buse JB Management of hyperglycemia in type 2 diabetes: a patient-centered approach Diabetes Care 2012 35 1364 1379 22517736
   PubMed Web of Science ®Google Scholar
• Garber AJ Abrahamson MJ Barzilay JI American Association of Clinical Endocrinologists’ comprehensive diabetes management algorithm 2013 consensus statement Endocr Pract 2013 19 Suppl 2 1 48 24129260
   PubMed Web of Science ®Google Scholar
• Krentz AJ Bailey CJ Oral antidiabetic agents: current role in type 2 diabetes mellitus Drugs 2005 65 385 411 15669880
   PubMed Web of Science ®Google Scholar
• Melander A Kinetics-effect relations of insulin-releasing drugs in patients with type 2 diabetes Diabetes 2004 53 Suppl 3 S151 S155 15561903
   PubMed Web of Science ®Google Scholar
• Carroll MF Izard A Riboni K Burge MR Schade DS Control of postprandial hyperglycemia Diabetes Care 2002 25 2147 2152 12453952
   PubMed Web of Science ®Google Scholar
• Defronzo RA From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus Diabetes 2009 58 773 795 19336687
   PubMed Web of Science ®Google Scholar
• Kahn S Haffner S Heise M Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy N Engl J Med 2006 355 2427 2443 17145742
   PubMed Web of Science ®Google Scholar
• Turner RC Holman RR Cull CA UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 1998 352 837 853 9742976
   PubMed Web of Science ®Google Scholar
• Rosenstock J Hassman DR Madder RD Repaglinide versus nateglinide monotherapy Diabetes Care 2004 27 1265 1270 15161773
   PubMed Web of Science ®Google Scholar
• Gallwitz B Glucagon-like peptide-1 analogues for type 2 diabetes mellitus: current and emerging agents Drugs 2011 71 1675 1688 21902291
   PubMed Web of Science ®Google Scholar
• Moretto TJ Milton DR Ridge TD Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naïve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study Clin Ther 2008 30 1448 1460 18803987
   PubMed Web of Science ®Google Scholar
• Russell-Jones D Cuddihy RM Hanefeld M Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naïve patients with type 2 diabetes (DURATION-4) Diabetes Care 2012 35 252 258 22210563
   PubMed Web of Science ®Google Scholar
• Blevins T Pullman J Malloy J DURATION-5: Exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes J Clin Endocrinol Metab 2011 96 1301 1310 21307137
   PubMed Web of Science ®Google Scholar
• Garber A Henry RR Ratner R Hale P Chang CT Bode B LEAD-3 (Mono) Study Group Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes Diabetes Obes Metab 2011 13 348 356 21205128
   PubMed Web of Science ®Google Scholar
• Garg R Chen W Pendergrass M Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin Diabetes Care 2010 33 2349 2354 20682680
   PubMed Web of Science ®Google Scholar
• Dore DD Seeger JD Chan AK Use of claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide Curr Med Res Opin 2009 25 1019 1027 19278373
   PubMed Web of Science ®Google Scholar
• Nauck MA Friedrich N Do GLP-1-based therapies increase cancer risk? Diabetes Care 2013 36 Suppl 2 S245 S252 23882053
   PubMed Web of Science ®Google Scholar
• Bode B Stenlöf K Sullivan D Fung A Usiskin K Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial Hosp Pract (1995) 2013 41 72 84 23680739
   PubMedGoogle Scholar
• Stenlöf K Cefalu WT Kim KA Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise Diabetes Obes Metab 2013 15 372 383 23279307
   PubMed Web of Science ®Google Scholar
• Inagaki N Kondo K Yoshinari T Maruyama N Sustuta Y Kuki H Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double blind, placebo-controlled, 12-week study Diabetes Obes Metab 2013 15 1136 1145 23782594
   PubMed Web of Science ®Google Scholar
• Pilodori D Sha S Mudaliar S Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion Diabetes Care 2013 36 2154 2161 23412078
   PubMed Web of Science ®Google Scholar
• Nisly SA Kolanczyk DM Walton AM Canagliflozin, a new sodium-glucose cotransporter 2 inhibitor, in the treatment of diabetes Am J Health Syst Pharm 2013 70 311 319 23370138
   PubMed Web of Science ®Google Scholar
• Misra M SGLT2 inhibitors: a promising new therapeutic option for treatment of type 2 diabetes mellitus J Pharm Pharmacol 2012 65 317 327 23356840
   PubMed Web of Science ®Google Scholar
• Burki T FDA rejects novel diabetes drug over safety fears Lancet 2012 379 507 22334883
   PubMed Web of Science ®Google Scholar
• Riser Taylor S Harris KB The clinical efficacy and safety of sodium glucose cotransporter-2 inhibitors in adults with type 2 diabetes mellitus Pharmacotherapy 2013 33 984 999 23744749
   PubMed Web of Science ®Google Scholar
• Irons BK Weis JM Stapleton MR Edwards KL An update in incretin-based therapy: a focus on dipeptidyl peptidase-4 inhibitors Curr Diabetes Rev 2012 8 169 182 22429011
   PubMedGoogle Scholar
• Karagiannis T Paschos P Paletas K Matthews DR Tsapas A Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis BMJ 2012 344 e1369 22411919
   PubMed Web of Science ®Google Scholar
• Esposito K Cozzolino D Bellastella G Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials Diabetes Obes Metab 2011 13 594 603 21320267
   PubMed Web of Science ®Google Scholar
• Scirica B Bhatt D Braunwald E Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus N Engl J Med 2013 369 1317 1326 23992601
   PubMed Web of Science ®Google Scholar
• Noel RA Braun DK Patterson RE Bloomgren GL Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes Diabetes Care 2009 32 834 838 19208917
   PubMed Web of Science ®Google Scholar
• Engel SS Williams-Herman DE Golm GT Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis Int J Clin Pract 2010 64 984 990 20412332
   PubMed Web of Science ®Google Scholar
• Chaisson JL Josse RG Hunt JA The efficacy of acarbose in the treatment of patients with non-insulin dependent diabetes mellitus Ann Intern Med 1994 121 928 935 7734015
   PubMed Web of Science ®Google Scholar
• Johnston PS Lebovitz HE Conniff RF Simonson DC Raskin P Munera CL Advantages of α-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients J Clin Endocrinol Metab 1998 183 1515 1522 9589648
   PubMed Web of Science ®Google Scholar
• Scott LJ Spencer CM Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus Drugs 2000 59 521 549 10776834
   PubMed Web of Science ®Google Scholar
• Buse J Hart K Minasi LA The PROTECT study: final results in a large multicenter postmarketing study in patients with type 2 diabetes Clin Ther 1998 20 257 269 9589817
   PubMed Web of Science ®Google Scholar
• Takami K Takeda N Nakashima K Effects of dietary treatment alone diet with voglibose or glyburide on abdominal adipose tissue and metabolic abnormalities in patients with newly diagnosed type 2 diabetes Diabetes Care 2002 25 658 662 11919121
   PubMed Web of Science ®Google Scholar
• Iwamoto Y Tajima N Kadowaki T Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial Diabetes Obes Metab 2010 12 613 622 20590736
   PubMed Web of Science ®Google Scholar
• Handelsman Y Role of bile acid sequestrants in the treatment of type 2 diabetes Diabetes Care 2011 34 Suppl 2 S244 S250 21525463
   PubMed Web of Science ®Google Scholar
• Smushkin G Sathananthan M Piccinini F The effect of a bile acid sequestrant on glucose metabolism in subjects with type 2 diabetes Diabetes 2013 62 1094 1101 23250357
   PubMed Web of Science ®Google Scholar
• Schwartz SL Lai YL Xu J The effect of colesevelam hydrochloride on insulin sensitivity and secretion in patients with type 2 diabetes: a pilot study Metab Syndr Relat Disord 2010 8 179 187 20059361
   PubMed Web of Science ®Google Scholar
• Fonseca VA Rosenstock J Wang AC Truitt KE Jones MR Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy Diabetes Care 2008 31 1479 1484 18458145
   PubMed Web of Science ®Google Scholar
• Goldberg RB Fonseca VA Truitt KE Jones MR Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy Arch Intern Med 2008 168 1531 1540 18663165
   PubMed Web of Science ®Google Scholar
• Rigby S Handelsman Y Lai Y Abby S Tao B Jones MR Effects of colesevelam, rosiglitazone, or sitagliptin on glycemic control and lipid profile in patients with type 2 diabetes mellitus inadequately controlled by metformin monotherapy Endocr Pract 2010 16 53 63 19789153
   PubMed Web of Science ®Google Scholar
• Goldfine AB Fonseca VA Jones MR Wang AC Ford DM Truitt KE Long-term safety and tolerability of colesevelam HCl in subjects with type 2 diabetes Horm Metab Res 2010 42 23 3- 19862667
   PubMed Web of Science ®Google Scholar
• Bays HE Long-term (52–78 weeks) treatment with colesevelam HCl added to metformin therapy in type 2 diabetes mellitus patients Diabetes Metab Syndr Obes 2012 5 125 134 22807633
   PubMedGoogle Scholar
• Holt RI Barnett AH Bailey CJ Bromocriptine: old drug, new formulation and new indication Diabetes Obes Metab 2010 12 1048 1057 20977575
   PubMed Web of Science ®Google Scholar
• DeFronzo RA Bromocriptine: a sympatholytic, D2-dopamine agonist for the treatment of type 2 diabetes Diabetes Care 2011 34 789 794 21447659
   PubMed Web of Science ®Google Scholar
• Pijil H Ohashi S Matsuda M Bromocriptine: a novel approach to the treatment of type 2 diabetes Diabetes Care 2000 23 1154 1161 10937514
   PubMed Web of Science ®Google Scholar
• Scranton R Cincotta A Bromocriptine – unique formulation of a dopamine agonist for the treatment of type 2 diabetes Expert Opin Pharmacother 2010 11 269 279 20030567
   PubMed Web of Science ®Google Scholar
• Kerr JL Timpe EM Petkewicz KA Bromocriptine mesylate for glycemic management in type 2 diabetes mellitus Ann Pharmacother 2010 44 1777 1785 20978217
   PubMed Web of Science ®Google Scholar
• Gaziano JM Cincotta AH O’Connor CM Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes Diabetes Care 2010 33 1503 1508 20332352
   PubMed Web of Science ®Google Scholar
• Gaziano JM Cincotta AH Vinik A Blonde L Bohannon N Scranton R Effect of bromocriptine-QR (a quick-release formulation of bromocriptine mesylate) on major adverse cardiovascular events in type 2 diabetes subjects J Am Heart Assoc 2012 1 e002279 23316290
   PubMed Web of Science ®Google Scholar
• Raccah D Options for the intensification of insulin therapy when basal insulin is not enough in type 2 diabetes mellitus Diabetes Obes Metab 2008 10 Suppl 2 76 82 18577159
   PubMed Web of Science ®Google Scholar
• Janka HU Plewe G Riddle MC Kliebe-Frisch C Schweitzer MA Yki-Järvinen H Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes Diabetes Care 2005 28 254 259 15677775
   PubMed Web of Science ®Google Scholar
• Ryan EA Imes S Wallace C Short-term intensive insulin therapy in newly diagnosed type 2 diabetes Diabetes Care 2004 27 1028 1032 15111515
   PubMed Web of Science ®Google Scholar
• Li Y Xu W Liao Z Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function Diabetes Care 2004 27 2597 2602 15504992
   PubMed Web of Science ®Google Scholar
• Chen HS Wu TE Jap TS Hsiao LC Lee SH Lin HD Beneficial effects of insulin on glycemic control and beta-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia after short-term intensive insulin therapy Diabetes Care 2008 31 1927 1932 18556343
   PubMed Web of Science ®Google Scholar
• Currie CJ Poole CD Evans M Peters JR Morgan CL Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes J Clin Endocrinol Metab 2013 98 668 677 23372169
   PubMed Web of Science ®Google Scholar
• Schernthaner G Currie CJ Schernthaner GH Do we still need pioglitazone for the treatment of type 2 diabetes? A risk-benefit critique in 2013 Diabetes Care 2013 36 Suppl 2 S155 S161 23882041
   PubMed Web of Science ®Google Scholar
• Pavo I Jermendy G Varkonyi TT Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes J Clin Endocrinol Metab 2003 88 1637 1645 12679450
   PubMed Web of Science ®Google Scholar
• Perez-Monteverde A Seck T Xu L Efficacy and safety of sitagliptin and the fixed-dose combination of sitagliptin and metformin vs pioglitazone in drug-naïve patients with type 2 diabetes Int J Clin Pract 2011 65 930 938 21849007
   PubMed Web of Science ®Google Scholar
• Wainstein J Katz L Engel SS Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes Diabetes Obes Metab 2012 14 409 418 22059736
   PubMed Web of Science ®Google Scholar
• Tan MH Baksi A Krahulec B Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes Diabetes Care 2005 28 544 550 15735185
   PubMed Web of Science ®Google Scholar
• Dormandy JA Charbonnel B Eckland DJ Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study Lancet 2005 366 1279 1289 16214598
   PubMed Web of Science ®Google Scholar
• Dormuth CR Carney G Carleton B Bassett K Wright JM Thiazolidinediones and fractures in men and women Arch Intern Med 2009 169 1395 1402 19667303
   PubMed Web of Science ®Google Scholar
• Idris I Warren G Donnelly R Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes Arch Intern Med 2012 172 1005 1011 22688528
   PubMedGoogle Scholar
• Neumann A Weill A Ricordeau P Fagot JP Alla F Allemand H Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study Diabetologia 2012 55 1953 1962 22460763
   PubMed Web of Science ®Google Scholar
• DeFronzo RA Eldor R Abdul-Ghani M Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes Diabetes Care 2013 36 Suppl 2 S127 S138 23882037
   PubMed Web of Science ®Google Scholar
• Glucophage (metformin hydrochloride tablets) FDA-approved label Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020357s031,021202s016lbl.pdf Accessed September 25, 2013
   Google Scholar
• United Kingdom Medicines and Healthcare Products Regulatory Agency Metformin Summary of Product Characteristics Available from: http://www.mhra.gov.uk/home/groups/spcpil/documents/spcpil/con1376454233492.pdf Accessed September 25, 2013
   Google Scholar